Overview

Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19

Status:
Recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate if adding rhC1-INH to standard of care (SOC) in patients admitted for stage II COVID-19 infection may reduce the risk of disease progression, i.e. ALI requiring mechanical ventilation, or increase the chance of a faster clinical improvement compared to SOC alone.
Phase:
Phase 2
Details
Lead Sponsor:
Pharming Technologies B.V.
Treatments:
Complement C1 Inhibitor Protein